UroToday.com - In the online edition of Urologic Oncology, Dr. Michael Cookson and his colleagues at Vanderbilt University reviewed the impact of surgeon and hospital volume on outcomes of radical prostatectomy (RP). They concluded that better outcomes are associated with higher volume surgeons and centers. The report is a literature review. Regarding hospital volume, there were no randomized trials identified, but 13 papers addressed the topic. Eight of the 13 addressed length of hospital stay, and all found that high-volume hospitals had a shorter mean length of stay. One meta-analysis reported a length of stay decrease of 0.9 days in high-volume centers.
UroToday.com - The metabolic syndrome is estimated to occur in 25-35% of U.S. adults and is defined by having >3 of the following 5 features; abdominal obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol, hypertension, and high fasting blood glucose. Studies suggest that the men with the metabolic syndrome are 50% more likely to be diagnosed with prostate cancer (CaP). This report by Jennifer Beebe-Dimmer and colleagues in the online version of Urology examined the association between the metabolic syndrome, its specific features, and CaP in a hospital-based, case-control study of white and African-American (AA) men residing in Detroit, Michigan.
Genzyme Corporation (Nasdaq: GENZ) announced that the European Commission has approved Renvela(R) (sevelamer carbonate) for the control of serum phosphorus in patients with chronic kidney disease (CKD). The approval includes patients not on dialysis with serum phosphorus levels greater than or equal to 1.78 mmol/L (5.5 mg/dL), and covers both the tablet and powder formulations. "With this marketing authorization, Renvela is the first phosphate binder for patients not on dialysis approved through the centralized procedure in Europe, " said Dan Regan, Senior Vice President and General Manager of Genzyme's renal business. "This is an important step toward improved patient care, and we are pleased that CKD patients in Europe will now have access to this proven therapy.
Cook Medical And LMA Urology Ltd Forge Global Partnership To Advance Global Treatment Of Stone Disease
Cook Medical and LMA Urology Ltd have entered into a strategic partnership that can significantly improve the remedies available for stone disease management. Through the worldwide agreement, Cook will market and distribute LMA's StoneBreakerTM, a portable pneumatic lithotripter for stone fragmentation. The StoneBreaker is a powerful, portable, easy-to manage and cost-effective lithotripter, and will be marketed in conjunction with Cook's own cutting-edge portfolio of stone management technologies and devices. Together, they provide urologists across the globe with highly effective, comprehensive solutions for treating kidney, ureteral and bladder stones.
UroToday.com - The mortality rate for prostate cancer is declining due to improvements in earlier detection and in local therapy strategies, however, the ability to predict the metastatic behavior of a patient's cancer, as well as to detect and eradicate disease recurrence remains some of the greatest clinical challenges in oncology. It is estimated that 25-40% of men undergoing radical prostatectomy will have disease relapse, often termed a biochemical recurrence as the first clinical indication a rising serum level of prostate specific antigen (PSA). The accurate identification of patients at risk for relapse would greatly facilitate the rational application of adjuvant treatment strategies.
Laparoscopic Radical Versus Partial Nephrectomy For Tumors 4cm: Intermediate-term Oncologic And Functional Outcomes
UroToday.com - Nephron-sparing surgery has become the well-accepted method for treating patients with localized tumor disease of the kidney. Laparoscopic partial nephrectomy (LPN) has evolved such that it is considered equivalent to open partial nephrectomy for tumors <4 cm. The researchers from Cleveland Clinic now demonstrate that LPN may be equally efficacious for localized renal tumors >4 cm. They had 110 patients with Stage T1b-T3N0M0 renal cell carcinoma treated with LRN (N=75) or LPN (N=35). As expected the LRN group had larger tumors and more T3a tumors with clear cell pathologic features. The median follow up was 57 months in the LRN group and 44 months in the LPN group.